Search results for "Endocrine System"

showing 10 items of 1530 documents

Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist…

2005

Background This descriptive study evaluates the impact on endometrial development of standard and high doses of a GnRH antagonist in stimulated cycles compared with GnRH agonist and natural cycles. Methods Thirty-one oocyte donors were treated with a combination of rFSH and 0.25 mg/day ganirelix (standard dose), 2 mg/day ganirelix (high dose) or 0.6 mg/day buserelin (long protocol). Vaginal progesterone (200 mg/day) was administered in the luteal phase. Endometrial biopsies were performed 2 and 7 days after HCG administration. Additional biopsies were carried out in a subset of 12 subjects, 2 and 7 days following the LH peak of their previous natural cycle. Biopsies were evaluated histologi…

AgonistAdultendocrine systemmedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classmedicine.medical_treatmentFertilization in VitroLuteal phaseBiologyLuteal PhaseEndometriumBuserelinChorionic GonadotropinGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneEndometriumOvulation InductionInternal medicinemedicineHumansUltrasonicsGanirelixOligonucleotide Array Sequence Analysismedicine.diagnostic_testOocyte DonationRehabilitationObstetrics and GynecologyBuserelinmedicine.anatomical_structureEndocrinologyReproductive MedicineGene Expression RegulationReceptors EstrogenMicroscopy Electron ScanningOocytesRNAOvulation inductionFemaleFollicle Stimulating HormoneReceptors Progesteronehormones hormone substitutes and hormone antagonistsmedicine.drugEndometrial biopsyHuman reproduction (Oxford, England)
researchProduct

Pretreatment with gonadotropin-releasing hormone (GnRH) antagonists to prevent the flare-up effect of long-acting GnRH agonists: results of a pilot s…

2007

This study evaluated in vivo whether the flare-up effect of GnRH agonists can be suppressed through pretreatment with a GnRH antagonist. The classic flare-up effect caused by 3.8 mg goserelin acetate could not be suppressed through pretreatment using a single dosage of 3.24 mg cetrorelix acetate.

AgonistMaleendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classPilot ProjectsGonadotropin-releasing hormoneGonadotropin-Releasing HormoneHormone AntagonistsIn vivoInternal medicinemedicineFlare upHumansTestosteroneEstradiolbusiness.industryGoserelin AcetateAntagonistObstetrics and GynecologyLuteinizing HormoneLong actingEndocrinologyTreatment OutcomeReproductive MedicineCetrorelixGoserelinFemaleFollicle Stimulating Hormone Humanbusinesshormones hormone substitutes and hormone antagonistsTranssexualismmedicine.drugFertility and sterility
researchProduct

GLP-2: What do we know? What are we going to discover?

2014

Glucagon-like peptide 2 [GLP-2] is a 33-amino acid peptide released from the mucosal enteroendocrine L-cells of the intestine. The actions of GLP-2 are transduced by the GLP-2 receptor [GLP-2R], which is localized in the neurons of the enteric nervous system but not in the intestinal epithelium, indicating an indirect mechanism of action. GLP-2 is well known for its trophic role within the intestine and interest in GLP-2 is now reviving based on the approval of the GLP-2R agonist for treatment of short bowel syndrome [SBS]. Recently it also seems to be involved in glucose homeostasis. The aim of this review is to outline the importance of neuroendocrine peptides, specifically of GLP-2 in th…

Agonistendocrine systemmedicine.medical_specialtyPhysiologymedicine.drug_classClinical BiochemistryEnteroendocrine cellBiologySettore BIO/09 - FisiologiaBiochemistryEnteric Nervous SystemCellular and Molecular NeuroscienceEndocrinologyInternal medicineGlucagon-Like Peptide 2medicineAnimalsHumansGlucose homeostasisReceptorInflammationdigestive oral and skin physiologyShort bowel syndromemedicine.diseaseIntestinal epitheliumGastrointestinal TractEndocrinologyGLP-2 GLP-2 receptor gastrointestinal tract enteric nervous systemEnteric nervous systemGastrointestinal functionNeurosciencehormones hormone substitutes and hormone antagonistsSignal TransductionRegulatory Peptides
researchProduct

The role of gonadotropin-releasing hormone in murine preimplantation embryonic development.

1999

Previous studies have established the presence of an extrahypothalamic GnRH in a variety of tissues. GnRH receptor is known to be present in the placenta, which produces and secretes the decapeptide from the very early stages of placentation. We hypothesized that GnRH may play a role in the preimplantation development of embryos. To examine this hypothesis, we assessed GnRH and GnRH receptor messenger RNA (mRNA; RT-PCR) and protein expression (Immunohistochemistry) in preimplantation murine embryos at various developmental stages. Furthermore, preimplantation murine embryos were cultured with GnRH agonist and antagonist in vitro to assess the influence of GnRH analogs on embryo development.…

Agonistendocrine systemmedicine.medical_specialtyanimal structuresTranscription Geneticmedicine.drug_classZygoteMice Inbred StrainsGonadotropin-releasing hormoneBiologyMorulaGonadotropin-Releasing HormoneEmbryonic and Fetal DevelopmentMiceEndocrinologyInternal medicinePlacentamedicineAnimalsBlastocystRNA MessengerMessenger RNAReverse Transcriptase Polymerase Chain ReactionEmbryogenesisPlacentationGene Expression Regulation DevelopmentalEmbryoEndocrinologymedicine.anatomical_structureBlastocystembryonic structureshormones hormone substitutes and hormone antagonistsReceptors LHRHEndocrinology
researchProduct

GnRH Analogues in the Prevention of Ovarian Hyperstimulation Syndrome

2012

The GnRH analogue (agonist and antagonist GnRH) changed ovarian stimulation. On the one hand, it improved chances of pregnancy to obtain more oocytes and better embryos. This leads to an ovarian hyper-response, which can be complicated by the ovarian hyperstimulation syndrome (OHSS). On the other hand, the GnRH analogue can prevent the incidence of OHSS: GnRH antagonist protocols, GnRH agonist for triggering final oocyte maturation, either together or separately, coasting, and the GnRH analogue may prove useful for avoiding OHSS in high-risk patients. We review these topics in this article.

Agonistendocrine systemmedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismOvarian hyperstimulation syndromeStimulationReview ArticleAndrologyOvarian Hyperstimulation SyndromeInternal medicinemedicineGnRH AntagonistPregnancyGnRH Agonistbusiness.industryPreventionGnRH AntagonistOocytemedicine.diseaseOvarian Stimulationmedicine.anatomical_structureEndocrinologyDisease preventionbusinesshormones hormone substitutes and hormone antagonistsInternational Journal of Endocrinology and Metabolism
researchProduct

Is ovarian stimulation detrimental to the endometrium?

2007

Ovarian stimulation in assisted reproduction technology produces lower implantation rates per embryo transferred than natural and ovum donation cycles, suggesting suboptimal endometrial development due to the abnormal concentrations of hormones used to recruit more oocytes. After the publication of several studies on the gene expression profile of endometrial receptivity in the natural cycle using microarray technology, researchers have investigated the impact of ovarian stimulation on the gene expression pattern of the endometrium. Ovarian stimulation cycles that use gonadotrophin-releasing hormone (GnRH) agonists and antagonists have been analysed in detail during the window of implantati…

Agonistendocrine systemmedicine.medical_specialtymedicine.drug_classStimulationBiologyEndometriumEndometriumOvulation InductionInternal medicineGene expressionmedicineHumansGeneUterine DiseasesObstetrics and GynecologyEmbryoGenomicsmedicine.anatomical_structureEndocrinologyReproductive MedicineGene Expression RegulationGene chip analysisFemaleDevelopmental BiologyHormoneReproductive biomedicine online
researchProduct

Manejo de la hiperglucemia con fármacos no insulínicos en pacientes adultos con diabetes tipo 2

2019

Resumen: El adecuado tratamiento de la diabetes mellitus tipo 2 (DM2) incluye la alimentación saludable y el ejercicio (150 min/semana) como pilares básicos. Para el tratamiento farmacológico, la metformina es el fármaco de elección inicial, salvo contraindicación o intolerancia; en caso de mal control, se dispone de 8 familias terapéuticas (6 orales y 2 inyectables) como posibles combinaciones. Se presenta un algoritmo y unas recomendaciones para el tratamiento de la DM2. En prevención secundaria cardiovascular se recomienda asociar un inhibidor del cotransportador sodio-glucosa tipo 2 (iSGLT2) o un agonista del receptor de glucagon-like peptide-1 (arGLP1) en pacientes con obesidad. En pre…

Agonistmedicine.medical_specialtymedicine.drug_class030204 cardiovascular system & hematologyOverweight:Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Diabetic Diet [Medical Subject Headings]GastroenterologyDiabetes tipo 2:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]03 medical and health sciences0302 clinical medicineFármacos antidiabéticos:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia [Medical Subject Headings]Internal medicineDiabetes mellitusmedicineGliclazide030212 general & internal medicineHiperglucemiaContraindicationlcsh:R5-920business.industryAntidiabetic drugs:Diseases::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]nutritional and metabolic diseases:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology Social::Life Style [Medical Subject Headings]Type 2 diabetesGeneral Medicinemedicine.diseaseSulfonylureaObesityHumanos:Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings]MetforminHyperglycemia:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents [Medical Subject Headings]medicine.symptomlcsh:Medicine (General)Family Practicebusinessmedicine.drug
researchProduct

Personality and Hypothalamic–Pituitary–Adrenal Axis in Older Men and Women

2020

Personality has been related to health and mortality risk, which has created interest in the biological pathways that could explain this relationship. Although a dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis has been associated with health outcomes and aging, few studies have explored the association between personality and HPA axis functioning in older adults. In addition, it has been suggested that sex could moderate the relationship between personality and HPA axis functioning. Thus, our aim was to analyze the relationship between the big five personality traits and the diurnal cortisol pattern in older adults, as well as sex differences in this relationship. To do so, 7…

Agreeablenessendocrine systemCortisol awakening responsemedia_common.quotation_subjectlcsh:BF1-990050105 experimental psychology03 medical and health sciences0302 clinical medicinemedicinePersonalityPsychology0501 psychology and cognitive sciencesneuroticismhypothalamic–pituitary–adrenal axisBig Five personality traitsconscientiousnessGeneral Psychologyolder adultsmedia_commonOriginal ResearchExtraversion and introversion05 social sciencesConscientiousnessNeuroticismmedicine.anatomical_structurelcsh:PsychologyextraversionPsychology030217 neurology & neurosurgeryHypothalamic–pituitary–adrenal axishormones hormone substitutes and hormone antagonistsClinical psychologyFrontiers in Psychology
researchProduct

Metabolic impact of adult-onset, isolated, growth hormone deficiency (AOiGHD) due to destruction of pituitary somatotropes.

2011

Growth hormone (GH) inhibits fat accumulation and promotes protein accretion, therefore the fall in GH observed with weight gain and normal aging may contribute to metabolic dysfunction. To directly test this hypothesis a novel mouse model of adult onset-isolated GH deficiency (AOiGHD) was generated by cross breeding rat GH promoter-driven Cre recombinase mice (Cre) with inducible diphtheria toxin receptor mice (iDTR) and treating adult Cre(+/-), iDTR(+/-) offspring with DT to selectively destroy the somatotrope population of the anterior pituitary gland, leading to a reduction in circulating GH and IGF-I levels. DT-treated Cre(-/-), iDTR(+/-) mice were used as GH-intact controls. AOiGHD im…

Anatomy and PhysiologyMousemedicine.medical_treatmentgh deficiencyMiceEndocrinology0302 clinical medicinefactor-iInsulinglucoseAge of OnsetInsulin-Like Growth Factor I2. Zero hunger0303 health scienceseducation.field_of_studyMultidisciplinarypancreatic beta-cellQRAnimal ModelsGHreceptor genehypothalamic expressionmedicine.anatomical_structureCarbohydrate MetabolismIntercellular Signaling Peptides and ProteinsMedicineincreased insulin sensitivityResearch ArticleHeparin-binding EGF-like Growth Factormedicine.medical_specialtymicediet-induced obesityDisfunción metabólicaSomatotropic cellSciencePopulationEndocrine System030209 endocrinology & metabolismBiologyCarbohydrate metabolismGrowth hormone deficiency03 medical and health sciencesModel OrganismsInsulin resistanceAnterior pituitaryreplacement therapyPituitary Gland AnteriorGrowth FactorsInternal medicinemedicineAnimalsObesityeducationBiologyNutrition030304 developmental biologyDiabetic EndocrinologyEndocrine PhysiologyInsulinDiabetes Mellitus Type 2Metabolyc disfunctionmedicine.diseaseHormonesMice Mutant StrainsSomatotrophsProlactinDietRatsDisease Models AnimalEndocrinologyPituitaryGrowth HormoneInsulin ResistanceEnergy IntakeEnergy MetabolismGHDPLoS ONE
researchProduct

Endometrial Receptivity in Natural and Controlled Ovarian-Stimulated Cycles

2011

The development of endometrial receptivity is a prerequisite for successful embryonic implantation in mammals. The receptive status is reached only during a short period of time in the midluteal phase, this being maximal 7 days after the endogenous peak of LH (LH+7), named as the window of implantation (WOI). At this time, the endometrial epithelium acquires the functional ability to support blastocyst adhesion. In ART, controlled ovarian stimulation (COS) induces lower implantation rates per embryo transferred than natural or ovum donation cycles, suggesting suboptimal endometrial development due to the abnormal endocrine/paracrine milieu. Researchers have investigated the functional genom…

AndrologyParacrine signallingmedicine.anatomical_structuremedicineEndocrine systemEmbryoStimulationBlastocystFunctional abilityBiologyEndometriumHormone
researchProduct